Loading organizations...
Key people at Dune Medical Devices.
Dune Medical Devices is a Caesarea, Israel-based medical technology company that develops proprietary tissue characterization devices to help surgeons, radiologists, and hospitals identify cancerous tissues in real-time during procedures. Operating additional offices in Paoli, Pennsylvania, and Alpharetta, Georgia, the firm designs and manufactures sensor-based tools used primarily in surgical oncology and minimally invasive procedures, such as lumpectomies, to facilitate the complete excision of malignant tissue. Prior to its acquisition, the privately held enterprise raised between $46 million and $100 million in total venture funding, including a $12.5 million Series B round, from lead investors such as Apax Partners, Aton Partners, and The Kraft Group. In April 2020, the business was officially acquired by Dilon Technologies to expand its portfolio of surgical oncology solutions. Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony.
Key people at Dune Medical Devices.
Dune Medical Devices developed and commercialized intraoperative, real-time cancer detection devices using proprietary radiofrequency (RF) spectroscopy technology to characterize tissue and identify cancerous margins during surgery[1][2][3]. The company's flagship product, MarginProbe, enabled surgeons to detect cancer at the surface of excised tissue in real-time during breast-conserving surgery, reducing the need for repeat procedures by allowing immediate additional tissue removal; it served oncological surgeons and patients undergoing lumpectomies, addressing the critical problem of incomplete cancer excision that affects up to 20-30% of cases[2][3][4]. Dune raised $46M before being acquired by Dilon Technologies in April 2020, marking the end of its independent growth phase with FDA approvals and clinical milestones like first-in-human Smart Biopsy trials[2][3][4].
Founded in 2002 in Israel, Dune Medical Devices emerged to harness its proprietary tissue characterization technology for surgical and diagnostic applications, starting with a focus on real-time cancer detection[2][5]. The core team leveraged RF spectroscopy to provide surgeons immediate feedback on tissue margins, with early developments including a breast cancer assessment probe announced in 2008 and FDA approval for an updated MarginProbe version[3]. Pivotal moments included receiving a European Union Horizon 2020 grant for its Smart Biopsy system—a percutaneous device for soft tissue biopsies—and completing first-in-human cases, alongside FDA pre-market approval for MarginProbe modifications, culminating in its acquisition by Dilon Technologies on April 2, 2020[2][3][4].
Dune rode the trend toward precision oncology and intraoperative imaging, where real-time diagnostics minimize surgical reinterventions amid rising demand for breast-conserving therapies over mastectomies[3][4]. Timing aligned with advances in RF spectroscopy and non-ionizing imaging modalities (e.g., alongside MRI and ultrasound in breast screening), fueled by market forces like FDA support for margin-detection tools and EU funding for innovative biopsies[2][3]. By influencing surgical standards—integrating with gamma probes for comprehensive tumor localization—Dune contributed to the medtech ecosystem's shift toward reducing healthcare costs and improving patient outcomes in a $10B+ global surgical oncology market[4].
Post-acquisition, Dune's assets like MarginProbe are integrated into Dilon Technologies' portfolio alongside Navigator Gamma Probes, enhancing synergistic sales for breast cancer solutions and likely expanding global adoption through Dilon's established network[4]. Trends in AI-augmented imaging and personalized surgery will shape its legacy, potentially evolving into next-gen hybrid devices for multi-cancer applications. As medtech consolidates around outcome-driven innovations, Dune's real-time detection tech continues powering fewer reoperations, tying back to its core mission of transforming intraoperative decisions for better patient lives.
